These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 29157513)
1. Antipsychotic augmentation for major depressive disorder: A review of clinical practice guidelines. Simons P; Cosgrove L; Shaughnessy AF; Bursztajn H Int J Law Psychiatry; 2017; 55():64-71. PubMed ID: 29157513 [TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. Patkar AA; Pae CU CNS Drugs; 2013 May; 27 Suppl 1():S29-37. PubMed ID: 23709359 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of new second generation antipsychotics for major depressive disorder. McElroy SL; Guerdjikova A; Mori N; Keck PE Expert Opin Investig Drugs; 2010 Dec; 19(12):1527-44. PubMed ID: 21105856 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. Taylor RW; Marwood L; Oprea E; DeAngel V; Mather S; Valentini B; Zahn R; Young AH; Cleare AJ Int J Neuropsychopharmacol; 2020 Dec; 23(9):587-625. PubMed ID: 32402075 [TBL] [Abstract][Full Text] [Related]
6. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855 [TBL] [Abstract][Full Text] [Related]
7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
8. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Wright BM; Eiland EH; Lorenz R Pharmacotherapy; 2013 Mar; 33(3):344-59. PubMed ID: 23456734 [TBL] [Abstract][Full Text] [Related]
9. Clinical issues in use of atypical antipsychotics for depressed patients. Pae CU; Patkar AA CNS Drugs; 2013 May; 27 Suppl 1():S39-45. PubMed ID: 23709360 [TBL] [Abstract][Full Text] [Related]
10. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Kane JM; Leucht S; Carpenter D; Docherty JP; J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142 [TBL] [Abstract][Full Text] [Related]
11. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study. Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435 [TBL] [Abstract][Full Text] [Related]
13. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial. Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689 [TBL] [Abstract][Full Text] [Related]
14. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Kennedy SH; Lam RW; McIntyre RS; Tourjman SV; Bhat V; Blier P; Hasnain M; Jollant F; Levitt AJ; MacQueen GM; McInerney SJ; McIntosh D; Milev RV; Müller DJ; Parikh SV; Pearson NL; Ravindran AV; Uher R; Can J Psychiatry; 2016 Sep; 61(9):540-60. PubMed ID: 27486148 [TBL] [Abstract][Full Text] [Related]
15. Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set. Gersing KR; Sheehan JJ; Burchett B; Zhu L; Bates JA; Baker RA; Kalsekar ID Psychiatr Serv; 2014 Aug; 65(8):1062-5. PubMed ID: 24932958 [TBL] [Abstract][Full Text] [Related]
16. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants]. Leblé N; Radon L; Rabot M; Godart N Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149 [TBL] [Abstract][Full Text] [Related]
17. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. Papakostas GI Essent Psychopharmacol; 2005; 6(4):209-20. PubMed ID: 16041917 [TBL] [Abstract][Full Text] [Related]
18. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials. Wang HR; Woo YS; Ahn HS; Ahn IM; Kim HJ; Bahk WM Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25770098 [TBL] [Abstract][Full Text] [Related]
19. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Nelson JC; Papakostas GI Am J Psychiatry; 2009 Sep; 166(9):980-91. PubMed ID: 19687129 [TBL] [Abstract][Full Text] [Related]
20. Antipsychotics as antidepressants. Roberts RJ; Lohano KK; El-Mallakh RS Asia Pac Psychiatry; 2016 Sep; 8(3):179-88. PubMed ID: 25963405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]